Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I
Abstract
CONTEXT: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is associated with insulin resistance and cardiovascular disease. Among the potential factors that may account for the increased cardiometabolic risk, IGF-I is a plausible candidate because the liver is the main site of its production. OBJECTIVE: Our objective was to examine the relationship between NAFLD and IGF-I levels and to test the hypothesis that free fatty acids-induced insulin resistance might impair insulin-induced increase of GH receptor (GHR) expression in human hepatoma cells. SUBJECTS, DESIGN, AND SETTING: Five hundred three nondiabetic Caucasians participated in this ambulatory-care cross-sectional study. MAIN OUTCOME MEASURES: Cardiometabolic risk factors and liver ultrasound scanning were assessed. Insulin-induced expression of GHR in HuH7 human hepatoma cells exposed for 24 h to palmitate was determined by Western blotting and real-time PCR. RESULTS: After adjustment for age and gender, individuals with NAFLD had significantly higher body mass index, waist circumference, fasting insulin, triglycerides, homeostasis model assessment index, liver enzymes, and lower high-density lipoprotein cholesterol compared with control subjects. IGF-I levels were significantly lower in individuals with NAFLD (P = 0.001). Exposure of HuH7 hepatoma cells to palmitate caused a dose-dependent reduction in the insulin-induced increase of GHR expression. CONCLUSIONS: These data show that IGF-I levels are reduced in subjects with NAFLD and suggest that hepatic insulin resistance may affect IGF-I levels by modulating GH-stimulated synthesis of hepatic IGF-I.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Studies have shown a reduction in IGF levels in patients with obesity and NAFLD.
“Studies have also shown a reduction in IGF levels in patients with obesity and NAFLD [237,238].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [237]
The citation lists haven’t been fetched yet
References 20 · Cited by 103
- Authors
- Arturi, F., Succurro, E., Procopio, C., Pedace, E., Mannino, G. C., Lugarà, M., Procopio, T., Andreozzi, F., Sciacqua, A., Hribal, M. L., Perticone, F., & Sesti, G.
- Affiliations
- Magna Graecia University (IT)
- Corresponding author
- Sesti, Giorgio
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-10
- Volume
- 96
- Issue
- 10
- Pages
- E1640-E1644
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2150669610
- Cited by
- 103
- References
- 20
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 7 · 2023: 7 · 2022: 11 · 2021: 3 · 2020: 7 · 2019: 9 · 2018: 4 · 2017: 9 · 2016: 10 · 2015: 5 · 2014: 10 · 2013: 9 · 2012: 4
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, insulin-like growth factor I, insulin resistance, growth hormone receptor, hepatic insulin signaling, palmitate, free fatty acids, cardiometabolic risk, Huh7 cells, hypertriglyceridemia, low HDL cholesterol
- MeSH terms
- Adult, Aged, Aging, Anthropometry, Cardiovascular Diseases, Cross-Sectional Studies, Dose-Response Relationship, Drug, Fatty Acids, Nonesterified, Fatty Liver, Female, Humans, Insulin Resistance, Insulin-Like Growth Factor I, Lipids, Male, Metabolic Diseases, Middle Aged, Receptors, Somatotropin, Risk Factors, Sex Characteristics, Ultrasonography, Cell Line, Tumor, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review